TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12297207
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (bean extract)
Study: 533575
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg antipyrine
Study: 533575
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg antipyrine
Study: 533575
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg antipyrine
Study: 24191873
Drug: Plasma of
Normalized name: HUMAN IGG POLYCLONAL ANTIBODY DERIVED FROM PLASMA OF TRANSCHROMOSOMAL BOVINE TARGETED TO THE SPIKE PROTEIN OF SARS COV-2
DrugBank: SAB-185 (DB16491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma of argon cleaning treatment
Study: 23289009
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (daily oral Zn supplements for eight weeks)
Study: 18976257
Drug: Alpha lipoic
Normalized name: Alpha Lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha lipoic acid (ALA) 800 mg day(-1) for 8 weeks
Study: 15124551
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (5-FU-CDDP)
Study: 15124551
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of the boost from 15 Gy to 25-25 Gy
Study: 10795929
Drug: Vasopressin V2
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin V2 antagonists
Study: 10795929
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (fluid restriction and treatment of underlying disorder)
Study: 1577025
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (20 mg.day‐1)
Study: 22486134
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg daily for 6 months
Study: 21138627
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group (without anti-viral therapy)
Study: 21138627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received lamivudine therapy)
Study: 21138627
Drug: Antiviral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral group (HBeAg negative)
Study: 21138627
Drug: Antiviral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral group (HBeAg positive)
Study: 21138627
Drug: Antiviral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral group
Study: 1932377
Drug: Interleukin-1 (IL-1)
Normalized name: interleukin-1 (IL-1) trap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF) treatment
Study: 20597558
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate injection plus thumb spica cast
Study: 16191750
Drug: Nicotine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (20 microg/kg) via nasal spray
Study: 16191750
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 microg/kg) via nasal spray
Study: 2321781
Drug: Ilioinguinal/iliohypogastric (IG/IH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal/iliohypogastric (IG/IH) nerve block with 0.25 ml/kg of 0.25% bupivacaine
Study: 2321781
Drug: Instillation nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation nerve block with up to 0.5 ml/kg of 0.25% bupivacaine
Study: 91434
Drug: cis-platinum, vinblastine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-platinum, vinblastine, and bleomycin combination chemotherapy
Study: 28052291
Drug: Yogurt containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt containing Lactobacillus gasseri OLL2716 (LG), 112 ml twice daily for 6 weeks
Study: 28052291
Drug: Placebo yogurt,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo yogurt, 112 ml twice daily for 6 weeks
Study: 21593577
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention (systemic corticosteroid for 2 weeks, inhaled corticosteroid for 16 weeks, bronchodilator(s))
Study: 21593577
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (current asthma treatment guidelines for 18 weeks)
Study: 17565246
Drug: Radiotherapy (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (doses more than 60 Gy) in post menopausal cases
Study: 17565246
Drug: Breast irradiation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast irradiation with concurrent chemotherapy
Study: 17565246
Drug: Chemotherapy first
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy first before irradiation
Study: 14748938
Drug: Lutein, beta-carotene,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein, beta-carotene, or lycopene (natural isolate capsules, 15 mg/d, 4 weeks)
Study: 14748938
Drug: Lycopene or
Normalized name: lycopene Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene or lutein (>2.00 micromol/l)
Study: 14748938
Drug: Carotenoids (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoids (0.50 to 1.00 micromol/l)
Study: 11240091
Drug: Single global
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single global assessment of treatment efficacy (5-point scale)
Study: 14715393
Drug: Aspirin 600/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600/650 mg
Study: 11180023
Drug: Rofecoxib 12.5
Normalized name: rofecoxib 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 12.5 mg, 25 mg, 50 mg
Study: 8742572
Drug: Acarbose (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (300 mg/daily)
Study: 8742572
Drug: Metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500 mg/daily)
Study: 31427334
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose lowering drugs (OGLDs) starting with metformin and supplemented as needed with glibenclamide.
Study: 31427334
Drug: Insulin therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin therapy.
Study: 27393274
Drug: Chemoembolization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoembolization with TANDEM™ loaded with 150 mg of doxorubicin
Study: 27393274
Drug: Chemoembolization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoembolization with TANDEM™ loaded with 100 mg of doxorubicin
Study: 27393274
Drug: High loading
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High loading group (150 mg doxorubicin)
Study: 21319602
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency (PRF) therapy
Study: 21319602
Drug: Electro-acupuncture (EA)
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture (EA) therapy
Study: 18379478
Drug: Afobazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afobazole (30 to 60 mg daily, mean 50 mg) for 6 weeks
Study: 16081755
Drug: Custom made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom made mouthguard (MG)
Study: 11851576
Drug: Raloxifene (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (both doses) in subset with increased cardiovascular risk
Study: 10209802
Drug: estradiol-noretisteron acetate
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol-noretisteron acetate treatment
Study: 7797785
Drug: 800 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micrograms of inhaled triamcinolone once daily at 3:00 PM (QD group)
Study: 7797785
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of inhaled triamcinolone four times a day (QID group)
Study: 23131574
Drug: Nonprotein calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprotein calorie (NPC) supplement (200-kcal daily)
Study: 21439167
Drug: Supralingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supralingual immunotherapy
Study: 21439167
Drug: Both SLIT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SLIT and supralingual immunotherapy
Study: 20032907
Drug: modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified constraint-induced movement therapy (mCIT)
Study: 16478570
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg daily for the first week, then 10 mg for 11 weeks)
Study: 9159420
Drug: CPA 2
Normalized name: Cyproterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA 2 mg with 35 microg of ethinylestradiol for 21 days each month (Diane group)
Study: 9159420
Drug: CPA 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA 50 mg, days 5‐15, and ethinylestradiol 50 microg, days 5‐25, each month (CPA group)
Study: 9159420
Drug: Decapeptyl 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decapeptyl 3.75 mg i.m. every 28 days with conjugated oestrogen 0.625 mg, days 1‐21, and medroxyprogesterone acetate 10 mg, days 12‐21 (GnRHa group)
Study: 8187240
Drug: LDL-apheresis combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-apheresis combined with lipid-lowering drugs
Study: 31942927
Drug: Inulin-type fructans
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin-type fructans (ITFs) treatment
Study: 21856267
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg, BID), amoxicillin (1000 mg, BID), clarithromycin (500 mg, BID) for 14 days, plus vitamin C (500 mg, BID) and vitamin E (200 IU, BID) for 30 days (Group A)
Study: 21856267
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg, BID), amoxicillin (1000 mg, BID), clarithromycin (500 mg, BID) for 14 days (Group B)
Study: 17631400
Drug: Pregabalin 150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150, 300, and 600 mg/day
Study: 16543744
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) diamorphine spray
Study: 16543744
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) diamorphine
Study: 8610901
Drug: Acetaminophen 600
Normalized name: acetaminophen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 600 mg and codeine 60 mg
Study: 26634642
Drug: RCT-18 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT-18 (180 mg, once weekly for 4 weeks)
Study: 23868016
Drug: Depression treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression treatment completion
Study: 15192622
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy for 30 months
Study: 9207749
Drug: BCG 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.05 mg + 6 x 10(8) KML
Study: 9207749
Drug: BCG 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.05 mg + 5 x 10(7) KML
Study: 9207749
Drug: BCG 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.01 mg + 5 x 10(7) KML
Study: 3731087
Drug: Cytarabine 2
Normalized name: cytarabine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine 2 g/m2/72 h by continuous infusion
Study: 3731087
Drug: Cytarabine 6
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 6 g/m2/72 h by continuous infusion
Study: 26885785
Drug: clin 1.0%-BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: clin 1.0%-BP 3.75% gel
Study: 26885785
Drug: adap 0.1%-BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: adap 0.1%-BP 2.5% gel
Study: 9401251
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg daily, 20 mg during diarrhea)
Study: 8429445
Drug: Modified bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified bovine lung surfactant extract (beractant), 4 doses administered.
Study: 8429445
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (equal volume of air administered).
Study: 20037567
Drug: milgamma in
Approvals — FDA: no, EMA: no, PMDA: no
Description: milgamma in combination with diclofenac
Study: 16810105
Drug: CytoFab (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: CytoFab (250 units/kg loading dose, followed by 50 units/kg every 12 hrs for 9 doses)
Study: 16810105
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 mg/kg human albumin)
Study: 11061539
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment with 6 IU/m2 body surface/day
Study: 11061539
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment with 3 IU/m2 body surface/day
Study: 11061539
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (both dosages)
Study: 11061539
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment in GHD children
Study: 8299405
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g EDTA per infusion over a period of 5‐9 weeks to a total of 57 g EDTA
Study: 2852945
Drug: Retinol palmitate
Normalized name: Retinol palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinol palmitate (300,000 I.U. daily)
Study: 18203048
Drug: Amisulpride 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 600 mg/day
Study: 20717044
Drug: Valdecoxib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (20 mg intravenous)
Study: 20717044
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN patch 10 mg/h)
Study: 16009103
Drug: Jianpi Qinghua
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianpi Qinghua Recipe (JPQHR) combined with routine therapy
Study: 12632840
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pravastatin per day
Study: 9785773
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preventive measures for soccer and running injuries
Study: 7974685
Drug: Ivermectin, 150‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin, 150‐200 micrograms/kg in a single dose
Study: 7974685
Drug: Albendazole, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole, 400 mg/d for 3 days
Study: 7974685
Drug: Ivermectin, 150‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin, 150‐200 micrograms/kg in a single dose (second treatment course)
Study: 3141982
Drug: 5 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 weekly fractions of 2 Gy without any prior laparotomy
Study: 3141982
Drug: 3 weekly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 weekly fractions of 3.3 Gy after laparotomy
Study: 26154086
Drug: Acarbose (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (12 mg/kg)
Study: 26154086
Drug: Trans‐chalcone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans‐chalcone (12 mg/kg)
Study: 18430910
Drug: Mitomycin-based treatment
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-based treatment (n = 341): fluorouracil (1000 mg/m2 on days 1-4 and 29-32) + mitomycin (10 mg/m2 on days 1 and 29) + radiotherapy (45-59 Gy)
Study: 18430910
Drug: Cisplatin-based treatment
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based treatment (n = 341): fluorouracil (1000 mg/m2 on days 1-4, 29-32, 57-60, and 85-88) + cisplatin (75 mg/m2 on days 1, 29, 57, and 85) + radiotherapy (45-59 Gy; start day = day 57)
Study: 8865702
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia (GOI)
Study: 8865702
Drug: Epidural (GOI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural (GOI + continuous epidural infusion 1.5% lidocaine, 5 ml . h‐1)
Study: 1371291
Drug: Finasteride (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (1, 5, 10, 50, or 100 mg/day for 7 days)
Study: 1371291
Drug: Finasteride (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (various doses)
Study: 1371291
Drug: Finasteride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (2 days treatment)
Study: 6653057
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg orally at bedtime for four days
Study: 6653057
Drug: Oxtriphylline 200
Normalized name: oxtriphylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxtriphylline 200 mg (equivalent to theophylline 135 mg) orally every eight hours for 10 doses
Study: 24624390
Drug: Full-mouth ultrasonic
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth ultrasonic debridement followed by monthly supportive periodontal therapy
Study: 24624390
Drug: Full-mouth ultrasonic
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth ultrasonic debridement followed by supportive periodontal therapy at 3-month intervals
Study: 19962354
Drug: Oxycodone 10
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10 mg/day
Study: 19962354
Drug: Pregabalin (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75, 150, 300, and 600 mg/day)
Study: 18953194
Drug: Workshop intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Workshop intervention consisting of discussions, didactic information, individual plan formulation, and strategies to cope with moral distress.
Study: 24223362
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus honey
Study: 15165934
Drug: irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: irbesartan 300 mg/day
Study: 2433081
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg orally 2 h before and 10 mg at the start of the infusion)
Study: 2433081
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg 3 h before the infusion)
Study: 27334415
Drug: Rejection treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rejection treatment including ATG
Study: 20180787
Drug: OCA (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA (omeprazole, clarithromycin, amoxicillin)
Study: 20180787
Drug: OLA (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLA (omeprazole, levofloxacin, amoxicillin)
Study: 20180787
Drug: OACM (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OACM (omeprazole, amoxicillin for 5 days, followed by omeprazole, clarithromycin, metronidazole for 5 days)
Study: 20180787
Drug: OALM (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OALM (omeprazole, levofloxacin, amoxicillin for 5 days, followed by omeprazole, levofloxacin, metronidazole for 5 days)
Study: 18706008
Drug: i.v./i.a. rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v./i.a. rt‐PA therapy
Study: 18706008
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (i.v./i.a. rt‐PA and i.v. rt‐PA)
Study: 16798444
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 30 mg diluted to 5 mL (group 5)
Study: 16798444
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 30 mg diluted to 10 mL (group 10)
Study: 16798444
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 30 mg diluted to 20 mL (group 20)
Study: 27001444
Drug: ONO-4232 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-4232 (various doses)
Study: 22508200
Drug: HES (130/0.4)
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES (130/0.4) 20 ml/kg + Tranexamic Acid (TA) 10 mg/kg over 30 minutes followed by 1 mg/kg/hr for 12 hours
Study: 22508200
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate + TA at same dose
Study: 22508200
Drug: HES (130/0.4)
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES (130/0.4) 20 ml/kg
Study: 20856830
Drug: Salmeterol-fluticasone 50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol-fluticasone 50/500 μg
Study: 19235434
Drug: Intravesical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical mitomycin C chemotherapy
Study: 19235434
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG immunotherapy
Study: 12842524
Drug: Preoperative steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative steroid treatment (protocol group)
Study: 10595648
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (20 ml per day, equivalent to 0.3 g omega‐6, 3.6 g omega‐3; omega‐6/omega‐3 ratio 0.1)
Study: 10595648
Drug: Soy lecithin
Normalized name: Soy Lecithin
DrugBank: Lecithin, soybean (DB14161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy lecithin supplement (25 g per day, equivalent to 1.5 g omega‐6, 0.5 g omega‐3; omega‐6/omega‐3 ratio 3)